Vernalis Announces Weight Loss in Phase I Study
Posted on: Friday, 14 September 2007, 09:00 CDT
UK biopharmaceutical company Vernalis has reported striking weight loss in volunteers over 16 days in its single and multiple ascending dose study of its obesity drug candidate.
The Phase I trial, which evaluated 66 obese and mildly obese volunteers, demonstrated clinically relevant reductions in body fat, energy intake and waist circumference. V24343 was generally well tolerated over the dose range, with no serious adverse effects.
Simon Sturge, CEO of Vernalis, stated: "We are very excited by these preliminary results which, if confirmed over longer studies, will be of significant benefit to overweight and obese patients. We stated from the outset of this trial that it is our intention to seek a partner for this program, a process which is enhanced by such promising data."
Measures of efficacy were taken in the multiple ascending dose study, in which patients were treated at four daily dose levels of 5mg, 15mg, 50mg and 100mg. In this trial, there were beneficial effects of V24343 at all dose levels across multiple parameters, including weight loss, waist circumference, body fat and energy intake.
Average weight loss after 16 days was 0.5kg for placebo, 2.6kg for 5mg V24343 and 5.0kg for 100mg V24343.
According to the company, further trials will be required to evaluate the long-term safety and efficacy of this product in the treatment of obesity.
Source: Datamonitor
Related Articles
- Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
- Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
- Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
- Behavioral Modification Programs Help Obese Children Manage Their Weight
- Nastech Completes Enrollment for Phase II Obesity Trial
- Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
- Genaera Corporation Begins Dosing in Phase 1 Trial of Obesity Compound Trodusquemine
- Results of Numerous Trials in Multiple Myeloma (MM) With Thalomid, Revlimid, and Velcade Proved Overwhelmingly Positive - ASCO Review Part II Featuring Key Studies on the Oncology Area
- Kosan Presents Data on KOS-953 From Single-Agent and Combination Clinical Trials in Multiple Myeloma at European Hematology Association Congress
- The Effects of Weight Loss and Weight Gain on Insulin-Like Growth Factor (IGF)-1 and IGF Binding Proteins in Premenopausal Women
 |
 |
User Comments (0)
RSS Feeds